Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced H...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Maio, Massimo, Daniele, Gennaro, Piccirillo, Maria Carmela, Giordano, Pasqualina, Signoriello, Giuseppe, Daniele, Bruno, Perrone, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712698/
https://www.ncbi.nlm.nih.gov/pubmed/24213324
http://dx.doi.org/10.3390/cancers4020549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712698/
https://www.ncbi.nlm.nih.gov/pubmed/24213324
http://dx.doi.org/10.3390/cancers4020549

Ejemplares similares